Identification, evaluation and treatment of prasugrel low-response after coronary stent implantation - A preliminary study

Thrombosis Research

Volumn 126, Issue 5, 2010, Pages

  Neubauer, Horst ^a   Kaiser, Andreas ^a   Busse, Birgit ^b   Mugge A ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b Center for Human Genetics   (Germany)

Author keywords

Clopidogrel; Cytochrome P450; Low Responder; Platelet aggregation; Prasugrel

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 3A4; PRASUGREL; PURINERGIC P2Y12 RECEPTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; BLEEDING; CONTROLLED STUDY; CORONARY STENT; DNA POLYMORPHISM; DRUG METABOLISM; DRUG SUBSTITUTION; FEMALE; GENE AMPLIFICATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; IMPLANTATION; LETTER; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; STENTS; THIOPHENES;

EID: 78149284637     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.06.005     Document Type: Letter

References (11)

1. J.T. Brandt, C.D. Payne, S.D. Wiviott, G. Weerakkody, N.A. Farid, and D.S. Small A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 66 2007 e9 e16
2. M. Cattaneo New P2Y12 blockers J Thromb Haemost 7 Suppl 1 2009 262 265
3. N.A. Farid, A. Kurihara, and S.A. Wrighton Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans J Clin Pharmacol 50 2010 126 142
4. J.L. Rehmel, J.A. Eckstein, N.A. Farid, J.B. Heim, S.C. Kasper, and A. Kurihara Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450 Drug Metab Dispos 34 2006 600 607
5. A. Sugidachi, T. Ogawa, A. Kurihara, K. Hagihara, J.A. Jakubowski, and M. Hashimoto The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite J Thromb Haemost 5 2007 1545 1551
6. P.A. Gurbel, and U.S. Tantry Drug insight: clopidogrel nonresponsiveness Nat Clin Pract Cardiovasc Med 3 2006 387 395
7. B.T. Ivandic, M. Sausemuth, H. Ibrahim, E. Giannitsis, M. Gawaz, and H.A. Katus Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention Clin Chem 55 2009 1171 1176
8. H. Neubauer, S. Lask, A. Engelhardt, and A. Mügge How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification Thromb Haemost 99 2008 357 362
9. T. Jernberg, C.D. Payne, K.J. Winters, C. Darstein, J.T. Brandt, and J.A. Jakubowski Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173
10. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
11. M. Ingelman-Sundberg, S.C. Sim, A. Gomez, and C. Rodriguez-Antona Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 2007 496 526